Scientist II, Product Applications Cell Microsystems, North Carolina, United States
Organoids can accelerate the drug discovery pipeline by offering more relevant models for understanding tissue development, modeling complex disease pathology, and testing drug sensitivity and toxicity. However, traditional organoid culture methods are inadequate because they are low throughput, ill-suited for single organoid imaging, create heterogenous populations of organoids, and limit downstream utility. Cell Microsystems is addressing these limitations by extending the capabilities of the CellRaft AIR® System and developing a new consumable that enables automated imaging, identification, and isolation of individual organoids. Using the 3D CytoSort® Array, organoids can be reliably tracked, imaged, and phenotypically analyzed using brightfield and fluorescent microscopy as they grow over time. Intact organoids can be released individually and transferred for use in downstream applications such as clonal organoid generation, parent organoid subcloning, cytotoxicity and drug screening, single-organoid RNA extraction for gene expression or transcriptomic analysis, and other uniquely enabled applications.